Using 3d bioprinting for Nipple Areola Complex (NAC) reconstruction

TeVido项目摘要/摘要 在全球范围内，2010年，乳腺癌发病率略高于100万。在美国 每年约有20万名妇女被诊断患有乳腺癌，近40%的妇女将接受 乳房切除手术，完全切除乳房。2010年，在美国，超过93,000个乳房 由于癌症，进行了重建。乳头乳晕复合体缺失的患者 接受癌症切除的(NAC)在乳房过后很长一段时间内继续经历心理痛苦 土丘重建已经进行，但目前可用的选择容易受到 乳头突起、颜色和可能需要重新手术的不可预测的程度 对称性和乳房轮廓变化的问题很常见。这样做的最终目的是 研究人员正在交付一种自体NAC移植物，这种移植物经过组织工程处理 这些常见的问题，它会有一层皮肤与色素沉着，以匹配现有的乳头 以及由体积稳定的脂肪(FAT)移植物层叠成单一产品的突起，用于 整形外科医生可以在一套设备上申请。整形外科医生向TeVido表示，有一种 对更好的解决方案的重大需求。第一阶段奖的研究目标将证明 提出的科学概念的可行性，并为工程开发工具和技术 定制色素皮肤(与乳晕相关)和定制形状的脂肪组织结构 (与乳头投影相关)。TeVido将调查并选择脂肪的最佳配方 通过体内容量保留、宿主反应和血管输注来衡量构建。 同时和独立地，TeVido的生物打印工艺将进行修改，以生产 着色的表皮层和形成的色素沉着的模式将在 体外培养。综合起来，这些目标是解决南澳两个主要问题的基础 只需一次小手术即可重建。在第二阶段，TeVido建议进一步 优化尺寸和投影参数，制定评估和重复性的方法 制作具有正确大小、颜色和纹理的构件。如果第一阶段成功， 第二阶段的工作应导致临床前动物研究。TeVido拥有强大的协作能力 与唯一一家为拉美裔服务的卡内基分类研究中心合作并促进研究 得克萨斯大学埃尔帕索分校，并将利用UTEP的新 生物医学工程设施。研究人员在组织方面有经验和专业知识 工程学，基于纤维蛋白的新生血管形成，在小鼠模型上测试的生物打印皮肤；以及 组织工程生物打印领域的领先权威。最后，TeVido是一家由女性创立的 引领科技业务。

TeVido Project Summary/Abstract Globally, in 2010, there were slightly more than 1 million incidences of breast cancer. In the US ~200,000 women are diagnosed with breast cancer annually and nearly 40% will undergo mastectomies, full removal of the breast. In the US in 2010, more than 93,000 breast reconstructions were performed due to cancer. Patients with loss of the nipple areola complex (NAC) from cancer excision continue to experience psychological distress long after breast mound reconstruction has taken place, yet currently available options are vulnerable to an unpredictable degree of loss of nipple projection, color and possible need for reoperation while issues with symmetry and breast-contour changes are common. The ultimate goal of this research is the delivery of an autologous NAC graft that has been tissue engineered to address these common issues, it will have a skin layer with pigmentation to match the existing nipple and a projection built of volume-stable adipose (fat) grafts layered into a single product for a plastic surgeon to apply in one setting. Plastic surgeons have indicated to TeVido that there is a significant need for a better solution. The research aims of the Phase I award will demonstrate viability of the scientific concepts proposed and develop tools and techniques for engineering custom pigmented skin (relevant to the areola) and custom shaped adipose tissue constructs (relevant to nipple projection). TeVido will investigate and select best formulation for adipose constructs as measured by in vivo volume retention, host reaction and vascular infusion. Concurrently and independently, TeVido's bioprinting processes will be modified to produce a pigmented epidermal layer and the pattern of pigmentation of the formation will be assessed in vitro. Combined, these aims are the basis for addressing the two primary problems in NAC reconstruction in one minor surgical intervention. In Phase II, TeVido proposes to further optimize size and projection parameters and develop methods to assess and reproducibly fabricate constructs with the correct size, color and texture. Should Phase I be successful, Phase II work should result in pre-clinical animal studies. TeVido has a strong collaboration with and promotes research at the only Hispanic-Serving, Carnegie classified Research University, the University of Texas at El Paso, and will perform the work leveraging UTEP's new BioMedical Engineering facilities. The researchers have experience and expertise in tissue engineering, fibrin based neo-vascularization, bioprinted skin tested on a mouse model; and a leading authority on bioprinting for tissue engineering. Finally, TeVido is a women-founded and led technology business.